Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Prestige sells three shampoo brands

This article was originally published in The Tan Sheet

Executive Summary

Prestige Brands Holdings sells three shampoo brands - Prell, Denorex Dandruff Shampoo andZincon Dandruff Shampoo - to Ultimark Products, the Irvington, N.Y.-based firm says Oct. 29. The brands, which make up 2 percent to 3 percent of the firm's annual sales, sold for $8 million with an additional payment of $1 million due Oct. 28, 2010. Prestige said it will use the proceeds to pay down its debt. "The successful sale of these businesses allows us to increase focus on our two larger segments, over-the-counter healthcare and household cleaning products, to enhance shareholder value," said President and CEO Matthew Mannelly. Prestige also notes board members Peter Mann and Vincent Hemmer resigned. Mann, the firm's founder and a former CEO and chairman, will pursue a new business opportunity, and Hemmer, a private equity owner of Prestige stock, resigned after his firm, GTCR Golder Rauner, significantly reduced its holdings, the firm said Oct. 27

You may also be interested in...

Startup Blacksmith Debuts With Luden's, PediaCare Acquisition From McNeil

Blacksmith Brands, led by industry veteran Peter Mann, launches with the acquisition of five OTC brands from Johnson & Johnson/McNeil Consumer, including Luden's throat lozenges and PediaCare children's cough/cold remedies

As COVID Vaccine Market Goes Private, US Government Can Still Help Firms Boost Sales

Pfizer and Moderna’s ‘endemic’ COVID vaccine market scenarios anticipate much higher booster rates than have been achieved so far, but performance for 2023 may be aided by the Biden Administration campaign to increase shots this winter.

Regeneron President Booed At Conference Over Comments Urging Focus On Innovation Before Access

Regeneron President George Yancopoulos got in a screaming match at Milken conference, arguing paying for cures is a secondary problem that should be tackled once such products are developed. He also talked about how he believes tech companies are helping to create some of America’s health crises.


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts